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Abstract
Background: The nephron number is thought to be associated with the outcome of chronic kidney disease (CKD).
If the nephron number can be estimated in the clinical setting, it could become a strong tool to predict renal
outcome. This study was designed to estimate the nephron number in CKD patients and to establish a method to
predict the outcome by using the estimated nephron number.
Methods/Design: The hypothesis of this study is that the estimated nephron number can predict the outcome of
a CKD patient. This will be a multicenter, prospective (minimum 3 and maximum 5 years follow-up) study. The
subjects will comprise CKD patients aged over 14 years who have undergone a kidney biopsy. From January 2011
to March 2013, we will recruit 600 CKD patients from 10 hospitals belonging to the National Hospital Organization
of Japan. The primary parameter for assessment is the composite of total mortality, renal death, cerebro-
cardiovascular events, and a 50% reduction in the eGFR. The secondary parameter is the rate of eGFR decline per
year. The nephron number will be estimated by the glomerular density in biopsy specimens and the renal cortex
volume. This study includes one sub-cohort study to establish the equation to calculate the renal cortex volume.
Enrollment will be performed at the time of the kidney biopsy, and the data will consist of a medical interview,
ultrasound for measurement of the kidney size, blood or urine test, and the pathological findings of the kidney
biopsy. Patients will continue to have medical consultations and receive examinations and/or treatment as usual.
The data from the patients will be collected once a year after the kidney biopsy until March 2016. All data using
this study are easily obtained in routine clinical practice.
Discussion: This study includes the first trials to estimate the renal cortex volume and nephron number in the
general clinical setting. Furthermore, this is the first prospective study to examine whether the nephron number
predicts the outcome of CKD patients. The results from this study should provide powerful new tools for
nephrologists in routine clinical practice.
Trial registration: UMIN-Clinical Trial Registration, UMIN000004784.
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Previous studies suggested that chronic kidney disease
(CKD) is one of the most important risk factors for cardio-
vascular disease among known other risk factors, such as
diabetes, hypertension, hyperlipidemia, obesity, smoking,
and lifestyle [1,2]. Furthermore, the number of the dialysis
patients resulting as a consequence of the progression of
CKD has been constantly increasing. Subsequently, the
medical costs for treatments for end-stage kidney disease
(ESKD) patients have also been increasing in Japan [3].
CKD is also regarded as a major public health problem
worldwide [4].
Low birth weight (LBW) is a risk factor for the pro-
gression of kidney diseases in compliance with the Bar-
ker hypothesis [5-9]. In particular, it is well-known that
glomerular changes of adults who were born with a
low birth weight show focal segmental glomerulo-
sclerosis [10]. The nephron number is correlated with
the birth weight [11,12]. Therefore, the reason why the
LBW affects the progression of CKD can be explained
by intra-glomerular hypertension, which is induced to
compensate for the small number of nephrons [13-15].
These previous data suggest that estimation of the
nephron number in CKD patients can be a useful tool
to predict their outcomes. However, nephrologists cur-
rently do not have any tools to determine the indivi-
dual nephron number of CKD patients under normal
clinical situations. Previously, estimating the total glo-
merular number was accomplished by a combination
of magnetic resonance imaging (MRI) and a biopsy to
measure the cortical glomerular volume fraction and
mean glomerular volume [16,17]. However, MRI is not
realistic to use in routine clinical practice because of
its high cost. In addition, in spite of the fact that mea-
suring both the cortical glomerular volume fraction
and mean glomerular volume are considered to be
appropriate parameters to accurately estimate the total
glomerular number in individual patients, these are
also unrealistic, because these procedures are very
time-consuming.
This PRONEP study was designed to establish a
method for predicting the renal outcome based on the
nephron number estimated in patients with CKD that
can be easily used in routine clinical practice. This is
the first prospective study to examine whether the
nephron number can predict the outcomes of CKD
patients. The nephron number will be estimated by the
glomerular density in biopsied samples and the volume
of the renal cortex, in which glomeruli exclusively exist.
In addition, this study includes one sub-cohort study to
develop an equation to calculate the renal cortex
volume, because there is currently no method to mea-
sure it in the typical clinical setting.
Methods and Design
Hypothesis
The nephron number, which is estimated from the glo-
merular density in kidney biopsy specimens and the
volume of the renal cortex, can predict the outcome of
a CKD patient (Figure 1).
Study design
In a multicenter, prospective (minimum 3 and maximum
5 years follow-up) study, approximately 600 patients with
CKD who undergo a kidney biopsy for their diagnosis
and will be enrolled from January 2011 to March 2013.
These CKD patients will be recruited from 10 hospitals
belonging to the National Hospital Organization of
Japan. The hospitals participating in this study are spread
throughout Japan (Hokkaido, Kanazawa, Chiba, Nagoya,
Kyoto, Osaka, Fukuoka, and Nagasaki prefectures). This
protocol was submitted to the UMIN-Clinical Trial
Registration on January 1, 2011, and its unique trial num-
ber is UMIN000004784.
Study participants
Participants will be eligible for inclusion if they (1) have
CKD according to the K/DOQI CKD Guidelines [18], (2)
are undergoing a needle biopsy of the kidney, (3) sign the
acceptance letter for participating in this study, (4) are
over 14 years old, (5) and their guardian has also signed
the letter if they are under 20 years old. Participants will
Figure 1 A schematic diagram of the PRONEP study.T h i ss t u d y
is the first prospective study to determine whether the nephron
number estimated by the glomerular density in kidney biopsy
specimens and the volume of the renal cortex can predict the
outcome of a CKD patient.
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Page 2 of 10be excluded for any of the following reasons: (1) severe
laterality in kidney size or function, for example, unilat-
eral kidney, severe unilateral kidney atrophy, functionally
unilateral kidney, and so on, (2) have had cancer, but the
patients are eligible if they are free from the cancer for
more than 1 year before the kidney biopsy.
In this study, the estimated glomerular filtration rate
(GFR) will be calculated using the following formula,
which was developed for Japanese subjects [19]:
eGFR(mL/min/1.73m2) = 194 × Age−0.287 × Cre−1.094(×0.739 infemals)
In this study, all attending CKD patients will undergo
a needle biopsy of the kidney for their diagnosis. There-
fore, although this protocol determines the exclusion
criteria by the patients’ CKD stage, most of the attend-
ing patients should not be in stage 4 or 5.
Data collection at the enrollment
Enrollment should be performed at the time of the kidney
biopsy after informed consent, followed by permission to
participate in this study, is obtained. All patients will
undergo: 1. a medical interview, 2. an ultrasound to mea-
sure the kidney size, 3. blood or urine tests, 4. a kidney
biopsy to investigate the pathological findings data at the
enrollment is shown in Figure 2. These examinations are
performed routinely in the typical clinical setting for CKD
patients receiving a kidney biopsy. In other words, no new
or special examinations are included in this study.
In the medical interview, the question about birth
weight may be difficult to answer, especially for elderly
patients. If the subjects cannot answer the question about
their birth weight, the question will be changed to
whether their birth weight was normal (equal to or over
2500 g) or not, because LBW is defined as a newborn
birth weight of less than 2500 g by the World Health
Organization.
Clinical follow-up and data collection
Patients will continue to have medical consultations and
will receive examinations and/or treatment as usual. We
will not direct physicians to prescribe any preferred drug,
examination, or to give any specific medical advice. We
will also not ban the physicians from prescribing any par-
ticular drugs.
The data for patients will be collected once a year
after the kidney biopsy, and will be followed until
March 2016. We will permit the data collected during
the antero-posterior three months of the day of the kid-
ney biopsy to be analyzed as well. The data collection
plan is shown in Figure 3.
In this study, a cerebro-cardiovascular event was defined
as an acute myocardial infarction, angina pectoris, and cer-
ebro-vascular diseases. In addition, in order for a
myocardial infarction to be reported in this study, it has to
fulfill at least two of the following: (1) chest symptoms, (2)
ECG changes, (3) elevated cardiac enzymes. Angina is
defined as the presence of ECG abnormalities with chest
symptoms and the need for catheter or surgical treatment.
Furthermore, a cerebro-vascular event is defined as cases
with neuropathy lasting more than 24 hours continuously
and with proof of a causative lesion by CT scan or MRI
(TIA and asymptomatic small infarction are not included).
If no data is tracked during the follow-up, the reason will
be recorded (stopped visiting the hospital, transferred to
another hospital, moved to a new house, offered to stop
the medical consultation, and so on).
Parameters for the assessment
The primary parameter that will be assessed is the com-
posite of the total mortality, renal death (starting main-
tenance hemodialysis and peritoneal dialysis, kidney
transplantation), cerebro-cardiovascular events (ischemic
heart disease, cerebral hemorrhage, cerebral infarction),
and a 50% reduction in the eGFR. The secondary para-
meter is the rate of eGFR decline per year.
Rationale for the number of patients
This study aims to predict the outcome of chronic kidney
disease using the estimated nephron number. We assumed
that the time from entry to event will be independently
and exponentially distributed. The planned sample size
was based on a two-tailed log-rank test with the signifi-
cance level set to 0.05, and the power level set at 0.80. The
ratio of low birth weight infants per total newborns in
Japan was reported to be 0.086 in 1960 and 0.097 in 2007.
During this period, the rate has been consistently increas-
ing http://www.mhlw.go.jp/english/database/db-hw/vs01.
html. The rate of LBW may be higher in the CKD patients
than in normal subjects. We assumed that the rate of
LBW would be 0.095 in the CKD patients in this study.
This study is planned with an accrual interval of 2 years,
and additional follow-up after the accrual interval of 3
years. The event rates were assumed to be 0.1 in the nor-
mal birth weight group and 0.2 in the low birth weight
group by several studies [8,20,21]. The required sample
size was therefore calculated to be 50 for the low birth
weight group and 476 for the normal birth weight group
[22]. Assuming that 10% of subjects would withdraw, we
used the simple number of 600 as the target number of
patients to recruit for this study.
Measurement of the kidney size by ultrasound imaging
We will record the major and the minor axis of the
longitudinal plane, and the diameter of the transverse
plane of the kidney by ultrasound examination as shown
in Figure 4. Only the size of the biopsied site will be
registered at enrollment.
Imasawa et al. BMC Nephrology 2012, 13:11
http://www.biomedcentral.com/1471-2369/13/11
Page 3 of 10Information from kidney biopsy specimens
As a general rule, sections stained by PAS or PAM-HE
will be used for the measurement of the glomerular
number and the length of the cortex (Figure 5). At the
time of the measurement, squared grids will be set in an
ocular lens, and thereafter, the length of the cortex will
be measured. In the formal definition, the cortex and
medulla are separated by the arcuate artery of the
(QUROOPHQW5HJLVWUDWLRQ)RUP,' 
7KHGDWHRINLGQH\ELRSV\GD\PRQWK\HDU
3DWLHQWDJHDWNLGQH\ELRSV\ 6H[䕕PDOH 䕕IHPDOH㻌 
%ORRGSUHVVXUHDWNLGQH\ELRSV\V\VWROLFGLDVWROLF
+HLJKW㻌㻌㻌㻌FP&XUUHQWERG\ZHLJKWNJ
%LUWKZHLJKWJ ,VWKHELUWKZHLJKWFRQILUPHG
  E\WKHPDWHUQDODQGFKLOGKHDOWKKDQGERRN" 䕕\HV䕕QR
 ,IWKHELUWKZHLJKWLVQRWUHPHPEHUHGSOHDVHFKHFNWKHER[EHORZ
 䕕XQGHUJORZELUWKZHLJKW䕕JRURYHU㻌 䕕XQNQRZQ
*HVWDWLRQDJHDWELUWKZHHNV 䕕XQNQRZQ
%RG\ZHLJKWDW\HDUVROGNJ䕕XQNQRZQ䕕XQGHU\HDUVROG

)DPLO\KLVWRU\RI&.'䕕\HV䕕QR,I\HV䕕KHPRGLDO\VLV㻌䕕 SHULWRQHDOGLDO\VLV㻌䕕 WUDQVSODQWDWLRQ
&RPRUELGLWLHVGLDEHWHVPHOOLWXV䕕\HV䕕QR㻌㻌㻌㻌㻌㻌㻌K\SHUWHQVLRQ䕕\HV䕕QR
8VDJHRIUHQLQDQJLRWHQVLQDOGRVWHURQHV\VWHPEORFNHU㻌㻌㻌䕕\HV䕕QR㻌䕕 XQNQRZQ
,QIRUPDWLRQIURPXOWUDVRXQG
/RQJLWXGLQDODUHDPDMRUD[LVFPPLQRUD[LVFP
7UDQVYHUVHDUHDD[LVFP
,QIRUPDWLRQIURPNLGQH\ELRSV\
%LRSVLHGVLGH䕕OHIW䕕ULJKW*DXJHRIWKHQHHGOH*
7RWDOFRUWH[OHQJWKLQELRSVLHGVSHFLPHQVPP
7RWDOJORPHUXODUQXPEHULQFOXGLQJJOREDOVFOHURVLV 1XPEHURIJOREDOO\VFOHURVHGJORPHUXOL
7KHSDWKRORJLFDOGLDJQRVLV

/DERUDWRU\GDWD7KHGDWHRIVDPSOLQJGD\PRQWK\HDU
6HUXPFUHDWLQLQHPJGO6HUXPF\VWDWLQ&PJGO+E$FPJGO
6HUXPXULFDFLGPJGO6HUXP/'/PJGO
8ULQDU\SURWHLQDVSURWHLQFUHDWLQLQHUDWLRVSRWXULQHJJ&UH
KRXUFUHDWLQLQHFOHDUDQFHPOPLQPP
KRXUSURWHLQH[FUHWLRQLQXULQHJGD\ 
Figure 2 Registration form at enrollment. The original Japanese form was translated to English.
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Page 4 of 10kidney. However, it is difficult to clearly discriminate
between the cortex and medulla because of the frequent
lack of the arcuate artery in the specimen. Therefore,
w ed e f i n et h el e n g t ho ft h ec o r t e xi nt h ek i d n e yb i o p s y
specimen as shown in Figure 5. The needle gage num-
ber is also recorded, so that we will know the width of
the specimen. The gross square area of the cortex in the
specimens can be calculated by the total length of the
cortex and the width. The total glomerular number and
the number of glomeruli with global sclerosis will also
be recorded. If the section has only one glomerulus, the
section is ignored. If the total glomerular number in all
Death:   䕕 yes     䕕 no      㻌㻌㻌㻌If yes, the date of event was :        /       /      (d/m/y ) 
Renal death:    䕕 yes     䕕 no      㻌㻌㻌㻌  If yes, the date of event was :        /       /      (d/m/y) 
Cerebro-cardiovascular event: 䕕 yes     䕕 no     㻌㻌㻌㻌㻌㻌  If yes, the date of event was :        /       /      (d/m/y)
        If  yes:          䕕dead     or     䕕 alive  
50% decrease in eGFR:䕕 yes     䕕 no㻌㻌㻌㻌㻌㻌㻌㻌㻌 If yes, the date of event was :        /       /      (d/m/y) 
 
Follow-up data     The date of sampling (d/m/y):        /       / 
Body weight:                        kg 
Usage of renin-angiotensin-aldosterone system blocker:  䕕yes    䕕no 㻌䕕 unknown 
Serum creatinine:             mg/dl      
Urinary protein as the protein/creatinine ratio (spot urine):              g/gCre  
If the patient data cannot be obtained, please report the reason why. 
䕕stopped visits            䕕hospital transfer            䕕moved  
䕕request to stop the medical consultation㻌   䕕others㻌䠄 㻌㻌㻌㻌㻌                                             㻌䠅  
Follow-up/Registration Form (              year(s) after kidney biopsy)  
                         ID:             -     
Figure 3 Registration form to report follow-up data. The original Japanese form was translated to English.
a 
b 
c 
A  B 
Figure 4 Measurement of the kidney size by ultrasound.( A) We first select an image where the renal hilum is clearly observed and the area
of longitudinal plane is at the maximum. In this image, the major axis (line “a”) and minor axis (line “b”) are measured. The line “b” should be
vertical to the major axis and pass through the center of the renal hilum. (B) Next, we select the maximum transverse image, which is almost a
circle, and passes through the center of the renal hilum. In this image, the transverse axis (line “c”) is measured.
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Page 5 of 10sections obtained is under 8, such cases will be consid-
ered insufficient for the analysis. In line with the usual
clinical procedure, the pathological diagnosis will be
performed and registered.
Estimation of the total nephron number in a kidney
Based on previous studies, we will first assume that
there is 31% volume shrinkage in the paraffin-embedded
specimens due to fixation in formalin [17,23,24]. There-
fore, we will take the quotient of the actual measured
values of the length by 0.883(=
3 √
1 − 0.31) for the cal-
culation below. Next, the volume of the glomerulus is
thought to shrink 43% in the biopsied specimens
because of the loss of arterial pressure and because of
paraffin embedding after fixation in formalin
[16,17,23,24]. Therefore, the actual axis of the glomeru-
lus is calculated by dividing the measurement axis by
0.829(=
3 √
1 − 0.43), and the value is used for the
numerical formula below.
The total number of glomeruli is estimated as follows:
The formula of the spherical volume can be derived
using integral calculus, i.e. disk integration to sum the
volumes V=
 r
−r π

r2 − x2
dx =
4
3
πr3,w h e r eri s
radius of the sphere, and π is the constant pi.
Similarly, the average area of the observed glomeruli
on one section in the biopsied specimen is estimated as
follows:
We assume that glomeruli less than 5 micrometers in
diameter cannot be counted. A sphere 2r in diameter is
cut off at both ends in parallel so that the diameter of a
section may be set to 2ro(5 μm). We observe only circles
parallel to the section of this solid, whose height is
defined as 2 h. Considering a 2 h-high cylinder whose
volume is equal to this solid, the cylindrical base area is
equal to the average cross-sectional area of this solid cut
at random parallel to the base of the solid (Figure 6).
Ah × 2h =
 h
−h
π

r2 -x 2
dx
cortex 
medulla 
a 
a 
b 
A B 
cortex 
medulla 
cortex 
Figure 5 Definition of the length of the cortex in this study.( A) The length of cortex is measured from the outermost glomerulus to the
innermost glomerulus. (B) When the medulla is sandwiched between cortices, the total of two lengths between the outermost glomerulus to
the innermost glomerulus is considered the length of the cortex in the section.
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Page 6 of 10where Ah is the average rea of the observed circle.
Hence, Ah is estimated by:
Ah =
1
2h
 h
−h
π

r2 -x 2
dx =
π
2h

r2x-
x3
3
h
−h
=
π
2h

2r2h-
2
3
h
3
	
= π(r2 −
h
2
3
)
Using the Pythagorean theorem, h=
√
r2 − r2
o
Where r is the glomerular radius and ro is the cut-off
value of the observed glomerular radius (Figure 6).
Substituting h with a function of r and ro gives:
Ah = π


r2 −

r2 − r2
o

3

= π

2
3
r2 +
1
3
r2
o
	
Acortex_s (Area of the cortex of the section in a biop-
sied specimen) is calculated as:
Acortex s =L a+b× db
Where db is the internal diameter of the biopsy needle
and La+b is “a+b ” in Figure 5 for the total cortex length
in biopsied specimens.
VF glom/cortex (Volume fraction of glomeruli/cortex) is
equal to AFglom/cortex (Area fraction of glomeruli/cortex
on the section).
VFglom/cortex =A F glom/cortex =
Ns × Ah
Acortex - b
Where Ns is the number of observed glomeruli in a
biopsied specimen.
Finally, the total number of glomeruli (Ntotal) was cal-
culated as:
Ntotal =
Totalglomerularvolume
oneaverageglomerularvolume
=
VFglom/cortex × VCortex
4
3
πr3
Where Vcortex is the volume of the cortex estimated by
MRI.
In this study, the value of r will be decided after calcu-
lating the means of approximately 5% of the attending
patients by random sampling. Therefore, “r” is not a
variable in the final calculation.
Figure 6 A hypothetical sphere of a glomerulus.
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Page 7 of 10Statistical analysis
All data are expressed as the means (SD). The primary
parameter for assessment is the composite of the total
mortality, renal death, cerebro-cardiovascular events,
and a 50% reduction in the eGFR. We will use a Cox
proportional hazard model for the analysis. We will
check for confounders, interactions and multicollinearity
among the independent variables. The final models will
be adjusted by all significant variables, as well as con-
founders and other baseline covariables judged to have
clinical importance. The secondary parameter is the rate
of eGFR decline per year. A multivariate regression ana-
l y s i sw i l lb eu s e df o rt h ea n a l y s i s .T h es i g n i f i c a n c el e v e l
on both sides in the hypothesis testing will be set at
0.05. The analyses will be performed using the SPSS sta-
tistics software program version 19.0. (IBM Corp.)
Sub-cohort study to establish an equation for the renal
cortex volume
Some of the participating patients will undergo MRI to
measure the cortex volume of their kidney, because MRI
is the safest procedure and has highest resolution to
separate the cortex from the medulla, as reported in
other studies [16,17]. However, it is unrealistic to per-
form MRI for all CKD patients because of its high cost.
Therefore, we will attempt to establish the equation to
calculate an approximate value of the kidney cortex
volume measured by MRI.
Measurement of the cortex volume by MRI
While MR imaging sometimes does not provide suffi-
c i e n tc o n t r a s tf o rt h es o f tt i s s u e s ,i nm a n yc a s e s ,i ti s
possible to distinguish the cortex and the pith of the
kidney by tomography. Therefore, we will image the
entire kidney with axial MRI, and calculate the renal
cortical volume by multiplying the slice thickness and
the slice number of the kidney which we measured on
each axis tomogram. For this purpose, we found that an
MR image that provided the best contrast between the
cortex and medulla of the kidney was obtained using
the following sequence: 2D Turbo FLASH TR = 1570
ms, TE = 2.74 ms, TI = 1000 ms, Flip Angle = 15°, Fat
sat (-). We will manually draw the ROI in the kidney,
and the regional choice in the axial image of the kidney
will be determined by specialized radiological technolo-
gists (with AZE virtual Place FUJIN workstation, AZE
Co. Ltd., Tokyo).
The calculations used for the renal cortical and whole
kidney volume are as follows:
Wholekidneyvolume =

Areaofthekidneyineachslice×slicethickness(sliceinterval)
Renalcortex volume =

Areaofthecortexineachslice×slicethickness(sliceinterval)
Discussion
Chronic kidney disease is regarded as public health pro-
blem throughout the world [4]. In this study, we will
mostly focus on the importance of the nephron number
as a predictor of the outcome of CKD patients. The
nephron numbers vary widely among individuals
[25,26]. One report described that the range is from
227,327 to 1,825,380 per kidney, which is an 8-fold dif-
ference [12]. Compensatory adaptation to a reduced
nephron number results in an increased single nephron
GFR and hyperfiltration. This mechanism was described
as the hyperfiltration theory by BM Brenner [14,27]. In
fact, it was shown that nephron number is associated
w i t ht h ep r o g r e s s i o no fC K D[ 2 5 ] .F u r t h e r m o r e ,m a n y
reports indicate that low birth weight is a risk factor for
the progression of CKD [6-9,13], which further empha-
sizes the importance of the nephron number, because
the nephron number is positively correlated with the
birth weight [11,12]. Therefore, we hypothesized that
the individual nephron number would be useful for pre-
dicting the outcome of CKD.
As mentioned above, although it is likely that estimat-
ing the nephron number will be useful to predict the out-
comes of CKD patients, it is currently not possible to
determine the nephron number in living subjects. It was
reported that the glomerular density is correlated with
the prognosis of IgA nephropathy [28]. Although the glo-
merular density probably correlates with the nephron
number, the individual renal cortex volume should lar-
gely affect the nephron number. In addition, all of the
previous clinical studies concerned with birth weight or
nephron number were retrospective. The purpose of this
study is to examine whether the estimated nephron num-
ber can predict the outcome of CKD patients. It will be
the first prospective study of this type ever to be
performed.
For this purpose, 3 obstacles will have to be overcome.
First, it is not possible to measure the renal cortex volume
in the normal clinical setting. To develop a method for
estimating this parameter, a one sub-cohort study is being
performed. MRI can differentiate the cortex from the
medulla because of its high resolution. Other studies also
evaluated the total nephron number of dog kidneys or
human donor kidneys by the cortex volume measured by
MRI [16,17]. However, we cannot perform MRI for all
CKD patients because it is too expensive and not always
available. For this purpose, we will first accurately measure
the renal cortex volume of some of the participating
patients by MRI. Next, we will establish a method to cal-
culate an approximate value of the renal cortex volume
measured by MRI. The estimating equation may consist of
the kidney size measured by ultrasound, patient sex,
eGFR, birth weight, present body weight, and so on. This
Imasawa et al. BMC Nephrology 2012, 13:11
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mining the cortex volume in the general clinical setting.
As a second step, we will need to estimate the nephron
number while the subjects are still alive. Although mea-
surements of the cortical glomerular volume fraction and
mean glomerular volume in individuals are most accurate
for calculating the glomerular density, such analyses are
unfortunately very time-consuming and therefore a diffi-
cult to routinely perform in general clinical situations.
Therefore, in this study, the total nephron number will be
estimated by performing simpler analyses of biopsied spe-
cimens as described above. As the final step, the capacity
of the estimated nephron number to predict the outcome
of CKD patients will be assessed. The primary parameter
for assessment is a composite of the total mortality, renal
death, cerebro-cardiovascular events, and 50% reduction
in the eGFR. The secondary parameter is the rate of eGFR
decline per year. All of these parameters affect the quality
of life and survival of CKD patients.
In this study, we aim to establish a method to predict
the outcome of CKD patients at the time of their kidney
biopsy. Therefore, the data collected during the follow-
up period will be restricted (Figure 3). Because body
weight may affect the serum creatinine level, we will
include this data. There is a possibility that we may also
analyze the impact of the urinary protein level and usage
of renin-angiotensin-aldosterone system blockers,
because both are major effectors of the prognosis of CKD
patients [29-31]. Therefore, these data will also be col-
lected. On the other hand, we also require a lot of data at
enrollment (Figure 2), all of which will be variables of the
equation used to calculate the renal cortex volume or
predict the CKD outcomes. We plan to develop an equa-
tion that can be used for all CKD patients. However,
nephrologists will likely need different equations for each
disease, for example, diabetic nephropathy, benign
nephrosclerosis, and IgA nephropathy. Therefore, we will
further analyze the data by individual diseases.
This study includes the first trials to estimate the renal
cortex volume and nephron number in the general clini-
cal setting. In addition, this study is the first prospective
study to examine whether the nephron number can pre-
dict the outcome of CKD patients. The results from this
study should provide powerful new tools for nephrolo-
gists in routine clinical practice.
Ethical approval
This study is being conducted in accordance with the
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